|Bid||0.0000 x 3200|
|Ask||0.0000 x 21500|
|Day's range||1.9000 - 2.0307|
|52-week range||1.3800 - 7.3300|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.25|
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700), following initial analyses of data from studies condu
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO)Q3 2022 Earnings CallNov 08, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and welcome to the Inovio third quarter 2022 results conference call.